AMGN

Amgen Inc. Press Releases

$139.38
*  
0.69
0.5%
Get AMGN Alerts
*Delayed - data as of Aug. 29, 2014  -  Find a broker to begin trading AMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
8/28/2014 9:15:00 AM - PR Newswire

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
8/28/2014 9:00:00 AM - PR Newswire

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
8/27/2014 9:15:00 AM - PR Newswire

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
8/19/2014 1:55:00 AM - PR Newswire

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
8/18/2014 5:17:00 PM - PR Newswire

Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy
8/14/2014 9:15:00 AM - PR Newswire

Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates
8/13/2014 4:12:00 PM - PR Newswire

Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma
8/13/2014 4:01:00 PM - PR Newswire

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
8/4/2014 7:30:00 AM - PR Newswire

RBCC 3D Bioprinting Partner Awarded Prestigious Grant
7/31/2014 6:54:00 AM - Business Wire

Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37
7/29/2014 4:37:00 PM - PR Newswire

Amgen Announces 2014 Third Quarter Dividend
7/25/2014 4:00:00 PM - PR Newswire

Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
7/25/2014 2:30:00 AM - PR Newswire

Amgen Announces Webcast of 2014 Second Quarter Financial Results
7/24/2014 4:00:00 PM - PR Newswire

Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
7/21/2014 10:00:00 AM - PR Newswire

Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
7/17/2014 4:01:00 PM - PR Newswire

Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia
7/1/2014 8:09:00 AM - PR Newswire

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
6/16/2014 4:03:00 PM - PR Newswire

Groundbreaking Collaborative Clinical Trial Launched
6/16/2014 9:00:00 AM - PR Newswire

Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
6/11/2014 5:00:00 PM - PR Newswire

Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer
6/9/2014 4:15:00 PM - PR Newswire

Amgen To Present At The Goldman Sachs Global Healthcare Conference
6/6/2014 4:15:00 PM - PR Newswire

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO
6/2/2014 7:44:00 AM - PR Newswire